These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 33304317)

  • 1. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
    Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.
    Gajate P; Alonso-Gordoa T; Martínez-Sáez O; Molina-Cerrillo J; Grande E
    Clin Transl Oncol; 2018 May; 20(5):561-569. PubMed ID: 29124519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
    Briest F; Grabowski P
    Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog inhibitor sonidegib potentiates
    Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
    BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
    Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
    Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
    Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
    Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
    Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
    Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
    Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
    Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.